Edinburgh cancer discovery accelerator Cumulus hires chief scientific officer with 'invaluable' skills
Drug discovery accelerator Cumulus Oncology has hired a chief scientific officer with “invaluable” skills and industry connections.
Edinburgh-headquartered Cumulus was founded in 2017 to create spin-out companies around novel anti-cancer therapies that are fast-tracked through development and target cancers that do not respond well to existing treatments.
Its newly appointed chief scientific officer, Ian Waddell, is a biochemist with “career-long expertise” in oncology-focused drug discovery. He was previously chief scientific officer, early discovery, at Nasdaq-listed global contract research group Charles River Laboratories.
Advertisement
Hide AdAdvertisement
Hide Ad